Your browser doesn't support javascript.
loading
Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
Freeman, James V; Simon, DaJuanicia N; Go, Alan S; Spertus, John; Fonarow, Gregg C; Gersh, Bernard J; Hylek, Elaine M; Kowey, Peter R; Mahaffey, Kenneth W; Thomas, Laine E; Chang, Paul; Peterson, Eric D; Piccini, Jonathan P.
Afiliação
  • Freeman JV; From the Yale University School of Medicine, New Haven, CT (J.V.F.); Duke Clinical Research Institute, Durham, NC (D.N.S., L.E.T., E.D.P., J.P.P.); Division of Research, Kaiser Permanente of Northern California, Oakland, CA (A.S.G.); Saint Luke's Mid America Heart Institute and University of Missour
  • Simon DN; From the Yale University School of Medicine, New Haven, CT (J.V.F.); Duke Clinical Research Institute, Durham, NC (D.N.S., L.E.T., E.D.P., J.P.P.); Division of Research, Kaiser Permanente of Northern California, Oakland, CA (A.S.G.); Saint Luke's Mid America Heart Institute and University of Missour
  • Go AS; From the Yale University School of Medicine, New Haven, CT (J.V.F.); Duke Clinical Research Institute, Durham, NC (D.N.S., L.E.T., E.D.P., J.P.P.); Division of Research, Kaiser Permanente of Northern California, Oakland, CA (A.S.G.); Saint Luke's Mid America Heart Institute and University of Missour
  • Spertus J; From the Yale University School of Medicine, New Haven, CT (J.V.F.); Duke Clinical Research Institute, Durham, NC (D.N.S., L.E.T., E.D.P., J.P.P.); Division of Research, Kaiser Permanente of Northern California, Oakland, CA (A.S.G.); Saint Luke's Mid America Heart Institute and University of Missour
  • Fonarow GC; From the Yale University School of Medicine, New Haven, CT (J.V.F.); Duke Clinical Research Institute, Durham, NC (D.N.S., L.E.T., E.D.P., J.P.P.); Division of Research, Kaiser Permanente of Northern California, Oakland, CA (A.S.G.); Saint Luke's Mid America Heart Institute and University of Missour
  • Gersh BJ; From the Yale University School of Medicine, New Haven, CT (J.V.F.); Duke Clinical Research Institute, Durham, NC (D.N.S., L.E.T., E.D.P., J.P.P.); Division of Research, Kaiser Permanente of Northern California, Oakland, CA (A.S.G.); Saint Luke's Mid America Heart Institute and University of Missour
  • Hylek EM; From the Yale University School of Medicine, New Haven, CT (J.V.F.); Duke Clinical Research Institute, Durham, NC (D.N.S., L.E.T., E.D.P., J.P.P.); Division of Research, Kaiser Permanente of Northern California, Oakland, CA (A.S.G.); Saint Luke's Mid America Heart Institute and University of Missour
  • Kowey PR; From the Yale University School of Medicine, New Haven, CT (J.V.F.); Duke Clinical Research Institute, Durham, NC (D.N.S., L.E.T., E.D.P., J.P.P.); Division of Research, Kaiser Permanente of Northern California, Oakland, CA (A.S.G.); Saint Luke's Mid America Heart Institute and University of Missour
  • Mahaffey KW; From the Yale University School of Medicine, New Haven, CT (J.V.F.); Duke Clinical Research Institute, Durham, NC (D.N.S., L.E.T., E.D.P., J.P.P.); Division of Research, Kaiser Permanente of Northern California, Oakland, CA (A.S.G.); Saint Luke's Mid America Heart Institute and University of Missour
  • Thomas LE; From the Yale University School of Medicine, New Haven, CT (J.V.F.); Duke Clinical Research Institute, Durham, NC (D.N.S., L.E.T., E.D.P., J.P.P.); Division of Research, Kaiser Permanente of Northern California, Oakland, CA (A.S.G.); Saint Luke's Mid America Heart Institute and University of Missour
  • Chang P; From the Yale University School of Medicine, New Haven, CT (J.V.F.); Duke Clinical Research Institute, Durham, NC (D.N.S., L.E.T., E.D.P., J.P.P.); Division of Research, Kaiser Permanente of Northern California, Oakland, CA (A.S.G.); Saint Luke's Mid America Heart Institute and University of Missour
  • Peterson ED; From the Yale University School of Medicine, New Haven, CT (J.V.F.); Duke Clinical Research Institute, Durham, NC (D.N.S., L.E.T., E.D.P., J.P.P.); Division of Research, Kaiser Permanente of Northern California, Oakland, CA (A.S.G.); Saint Luke's Mid America Heart Institute and University of Missour
  • Piccini JP; From the Yale University School of Medicine, New Haven, CT (J.V.F.); Duke Clinical Research Institute, Durham, NC (D.N.S., L.E.T., E.D.P., J.P.P.); Division of Research, Kaiser Permanente of Northern California, Oakland, CA (A.S.G.); Saint Luke's Mid America Heart Institute and University of Missour
Circ Cardiovasc Qual Outcomes ; 8(4): 393-402, 2015 Jul.
Article em En | MEDLINE | ID: mdl-26058720
BACKGROUND: Instruments to assess symptom burden and quality of life among patients with atrial fibrillation (AF) have not been well evaluated in community practice or associated with patient outcomes. METHODS AND RESULTS: Using data from 10 087 AF patients in the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF), symptom severity was evaluated using the European Heart Rhythm Association (EHRA) classification system, and quality of life was assessed using the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire. The association between AF-related symptoms, quality of life, and outcomes was assessed using Cox regression. The majority of AF patients (61.8%) were symptomatic (EHRA >2) and 16.5% had severe or disabling symptoms (EHRA 3-4). EHRA symptom class was well correlated with the AFEQT score (Spearman correlation coefficient -0.39). Over 1.8 years of follow-up, AF symptoms were associated with a higher risk of hospitalization (adjusted hazard ratio for EHRA ≥2 versus EHRA 1 1.23, 95% confidence interval, 1.15-1.31) and a borderline higher risk of major bleeding. Lower quality of life was associated with a higher risk of hospitalization (adjusted hazard ratio for lowest quartile of AFEQT versus highest 1.49, 95% confidence interval, 1.2-1.84), but not other major adverse events, including death. CONCLUSIONS: In a community-based study, most patients with AF were symptomatic and had impaired quality of life. Quality of life measured by the AFEQT correlated closely with symptom severity measured by the EHRA class. AF symptoms and lower quality of life were associated with higher risk of hospitalization but not mortality during follow-up.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pacientes Ambulatoriais / Qualidade de Vida / Fibrilação Atrial / Sistema de Registros / Hospitalização Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pacientes Ambulatoriais / Qualidade de Vida / Fibrilação Atrial / Sistema de Registros / Hospitalização Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article